secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001193125-25-283182
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene prices $130M public offering of common shares and pre-funded warrants
----------------------------------------------------------------------------

- Pricing of 12,558,823 common shares at $8.50/share and pre-funded warrants for 2,735,295 shares at $8.4999 each.
- Gross proceeds expected ~$130M before underwriting discounts and expenses.
- Underwriters granted 30-day option to purchase up to 2,294,117 additional common shares.
- Offering expected to close on or about November 14, 2025.
- Proceeds to advance clinical-stage genetic medicines pipeline, including lead NMIBC candidate detalimogene.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312525283182/0001193125-25-283182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312525283182/d876714d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-283182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer